Graves Light Lenhart Wealth Inc. Reduces Position in Danaher Co. (NYSE:DHR)

Graves Light Lenhart Wealth Inc. reduced its holdings in Danaher Co. (NYSE:DHR) by 9.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,262 shares of the conglomerate’s stock after selling 139 shares during the period. Graves Light Lenhart Wealth Inc.’s holdings in Danaher were worth $290,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Teachers Insurance & Annuity Association of America purchased a new position in Danaher in the 3rd quarter worth approximately $39,000. MidAtlantic Capital Management Inc. purchased a new position in Danaher during the third quarter worth approximately $40,000. FSA Wealth Management LLC acquired a new position in Danaher during the third quarter worth $50,000. Darwin Wealth Management LLC purchased a new stake in Danaher in the 3rd quarter valued at $55,000. Finally, Modus Advisors LLC purchased a new stake in Danaher in the 4th quarter valued at $56,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Up 2.0 %

DHR stock opened at $239.83 on Tuesday. Danaher Co. has a fifty-two week low of $222.53 and a fifty-two week high of $281.70. The company’s 50 day moving average price is $235.52 and its 200 day moving average price is $253.65. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The firm has a market capitalization of $173.22 billion, a price-to-earnings ratio of 45.77, a PEG ratio of 4.32 and a beta of 0.83.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The company’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.02 EPS. On average, equities research analysts anticipate that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be given a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. Danaher’s dividend payout ratio is currently 20.61%.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on DHR. Citigroup lowered their price target on shares of Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. KeyCorp increased their price target on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. Wolfe Research upgraded shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target for the company in a report on Thursday, October 31st. Bank of America upgraded shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective on the stock in a report on Friday, December 13th. Finally, Guggenheim assumed coverage on shares of Danaher in a report on Thursday, December 19th. They issued a “buy” rating and a $275.00 target price for the company. Six analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $286.80.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.